FDA approves Keytruda monotherapy in third-line SCLC: https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-104500587.html This is an accelerated approval based on data from the KEYNOTE-158 and KEYNOTE-028 studies.